In recent years, we have developed a unique OncoProbe Platform, a novel tool for the preclinical evaluation of anticancer agents and modern immunotherapies like CAR-T cells. Our platform integrates advanced mouse xenograft models (PDX) and a biobank of primary cells and PDX derived from patients with hematological malignancies. Collaborating with prominent national and European centers, we've developed state-of-the-art techniques for assessing therapy efficacy, both in vitro and in vivo. Our current research focuses on refining high-throughput methodologies to evaluate the efficacy and specificity of various chemo-immunotherapy combinations against leukemia cells. Furthermore, the Platform serves for testing innovative therapies within the EIC Pathfinder consortium project ("Bottom-up Manufacturing of Artificial Anti-Tumor T Cells", ArtCell).